Clinical Trials Browser

NIH × Neoplasm, Residual × Clear all

NCT05642195 2026-03-18

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Phase 1/2 Suspended

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

Phase 2 Active not recruiting

175 enrolled 16 charts

Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Phase 2 Active not recruiting

69 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

NCT02054104 2022-01-26

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

Phase 1/2 Terminated

21 enrolled 11 charts

DermatologicSarcoma

Melanoma, Sarcoma, Neoplasm, Residual

NCT00339898 2019-12-17

Prognostic Value of a Positive RT-PCR Test in Patients With Ewing Sarcoma

Sarcoma, Ewing, Neoplasm, Residual

NCT02527447 2019-10-30

Biomarkers for Personalized Early Assessment of Response During Salvage Chemotherapy in People With Relapsed or Refractory Acute Myeloid Leukemia (PEARL15)

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual